Study to test a new drug to treat patients with Pulmonary Arterial Hypertension (PAH).

Phase 1

• Conditions: Pulmonary arterial hypertension; MedDRA version: 20.0 Level: PT Classification code 10064911 Term: Pulmonary arterial hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders; MedDRA version: 20.0 Level: LLT Classification code 10077739 Term: Pulmonary arterial hypertension WHO functional class I System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders; MedDRA version: 20.0 Level: LLT Classification code 10077729 Term: Pulmonary arterial hypertension WHO functional class III System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders; MedDRA version: 20.0 Level: LLT Classification code 10077740 Term: Pulmonary arterial hypertension WHO functional class II System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2017-000212-41-ES
• Lead Sponsor: GlaxoSmithKline, S.A.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-06-22
• Last Update Posted: 30 June 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:
Age
1. Participant must be between 18-75 years of age (inclusive), at the time of signing the informed consent
Type of Participant and Disease Characteristics
2. Documented diagnosis of PAH, defined as mPAP > 25 mmHg and PWP = 15 mmHg.
3. IPAH, HPAH, or PAH associated with collagen vascular disease, repaired congenital heart disease, or appetite suppressant use.
- Note: Those with portopulmonary hypertension or PVOD are not eligible for the study
4. World Health Organization (WHO) functional class I, II, or III, stable for at least 8 weeks prior to enrollment.
5. Hemodynamically stable on background therapy without evidence of right heart failure (historic data).
6. Six minute walk (6MW) distance, as performed at screening or within 6 months prior to screening, of > 100 meters
7. Mean BP of >60 mmHg
8. Receiving stable doses of one or more medications that are approved for treatment of PAH, including endothelin receptor antagonists, phosphodiesterase 5 inhibitors, and/or prostanoids/prostacyclin receptor agonists, for a minimum of 12 consecutive weeks before enrollment.
NOTE: Anticoagulant therapy can be adjusted according to target INR
9. Diuretic dose stable for 8 weeks.
Weight
10. Body weight <90 kg and body mass index (BMI) within the range 18-30 kg/m2 (inclusive).
Sex
11. Male and/or female (following confirmation of negative pregnancy test for WOCBP). Women who are pregnant or breastfeeding are excluded.
Informed Consent
12. Capable of giving signed informed consent as described in Appendix 3 (within the protocol) which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 21
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 3

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
1. History of systemic hypotension, defined as systolic BP <90 mmHg and/or diastolic BP <50 mmHg.
2. Hospitalization for PAH associated deterioration in the previous 6 months.
3. Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities.
Concurrent disease or condition that may interfere with study participation or safety include bleeding disorders, arrhythmia, organ transplant, organ failure, current neoplasm, poorly controlled diabetes mellitus, and serious neurological disorders.
4. Complex unrepaired congenital heart disease.
5. Subjects with Eisenmenger physiology.
6. Alanine transferase (ALT) >2x upper limit of normal (ULN).
7. Bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
8. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
9. Estimated glomerular-filtration-rate (eGFR) <60mL/min/1.73m2.
10. QTc >480 msec or QTc > 500 msec in participants with bundle branch block.
NOTES:
-The QTc is the QT interval corrected for heart rate according to Bazett’s formula (QTcB), Fridericia’s formula (QTcF), and/or another method. It is either machineread or manually over-read.
-The specific formula used to determine eligibility and discontinuation for an individual participant should be determined prior to initiation of the study. In other words, several different formulas cannot be used to calculate the QTc for an individual participant and then the lowest QTc value used to include or discontinue the participant from the trial.
11. Any bleeding concerns as evidenced by INR >1.5 (in participants not receiving anticoagulation therapy) or platelet count <80,000.
12. Hb <10 g/dL
Prior/Concomitant Therapy
13. Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates participation in the study.
14. Any use of an ACE inhibitor or angiotensin receptor blocker within 14 days prior to dosing. Therapy can be stopped to enable inclusion if deemed safe by the participant’s treating physician.
Prior/Concurrent Clinical Study Experience
15. Use of any investigational product (IP) or device within 30 days prior to dosing, or known requirement for any investigational agent prior to completion of all scheduled study assessments.
Diagnostic assessments
16. Positive HIV antibody test.
17. Presence of Hepatitis B surface antigen (HBsAg) at screening.
18. Positive Hepatitis C antibody test result at screening or within 3 months prior to starting study treatment.
-NOTE: Participants with positive Hepatitis C antibody due to prior resolved disease can be

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified